Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flerobuterol SCHEMBL249507 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL20819557 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL30956705 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL10624514 | 0.98 | BLM (0.67) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956709 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819687 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956714 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL9820962 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819586 | 0.85 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819585 | 0.85 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-09 | — | — | US | disclosed |
| EP-4605396-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Shanghai Curegene Pharmaceutical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025119207-A1 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2025-06-12 | — | — | WO | disclosed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| EP-4139294-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| WO-2025011656-A1 | ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2025-01-16 | — | — | WO | disclosed |
| WO-2022221686-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-11472793-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-13 | — | — | US | disclosed |
| US-20220324844-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-10-13 | — | — | US | disclosed |
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-24 | — | — | US | disclosed |
| US-11260049-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| US-11229623-B2 | TRPV4 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11260049-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | ADRB1 1180/4885ADRB2 1126/4885HIF1A 1995/4885 |
| US-20220089590-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | ADRB1 871/4885ADRB2 965/4885HIF1A 439/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | ADRB1 4764/4885ADRB2 4825/4885HIF1A 3211/4885 |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | ADRB1 4867/4885ADRB2 4846/4885HIF1A 3242/4885 |
| US-20220324875-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | ADRB1 2903/4885ADRB2 3588/4885HIF1A 3161/4885 |
| US-20250084077-A1 | ETHER LINKED TRIAZOLES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | ADRB1 871/4885ADRB2 965/4885HIF1A 439/4885 |
| US-20220204526-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ADRB1 97/4885ADRB2 57/4885HIF1A 869/4885 |
| US-20220162194-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | ADRB1 4867/4885ADRB2 4846/4885HIF1A 3242/4885 |
| US-11472793-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | ADRB1 4867/4885ADRB2 4846/4885HIF1A 3242/4885 |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | ADRB1 97/4885ADRB2 57/4885HIF1A 869/4885 |
| US-20220324844-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | ADRB1 4867/4885ADRB2 4846/4885HIF1A 3242/4885 |
| US-11229623-B2 | TRPV4 antagonists | TRPV4, TRPV5, TRPV2 | ADRB1 1180/4885ADRB2 1126/4885HIF1A 1995/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | ADRB1 708/4885ADRB2 1086/4885HIF1A 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.